Kyle Gano, Chief Business Development Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 12,160 shares at $79.67 ($980K) on 2022-02-08, disclosed to the SEC on 2022-02-09.
Seasonal sale ($980k) by Chief Business Development Officer — this insider has traded NBIX in February in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $80.68 | 703 | $57K | 5.8% |
| 2 | $80.68 | 703 | $57K | 5.8% |
| 3 | $80.77 | 1,600 | $129K | 13.2% |
| 4 | $80.78 | 1,623 | $131K | 13.4% |
| 5 | $80.78 | 1,623 | $131K | 13.4% |
| 6 | $80.80 | 1,974 |
| $159K |
| 16.3% |
| 7 | $80.80 | 1,974 | $159K | 16.3% |
| 8 | $79.67 | 980 | $78K | 8.0% |
| 9 | $79.67 | 980 | $78K | 8.0% |
| Total | $80.59 avg | 12,160 | $980K | 100% |
| Filing → |
| NBIX | SELL | 2025-02-14 | $598K | — | Filing → |
| NBIX | SELL | 2025-02-12 | $232K | — | Filing → |
| NBIX | SELL | 2025-02-04 | $471K | — | Filing → |